Literature DB >> 11691809

Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer.

J A Coronella1, P Telleman, G A Kingsbury, T D Truong, S Hays, R P Junghans.   

Abstract

A minority of breast cancers is characterized by lymphoplasmacytic infiltrates that have been correlated with improved patient survivals. The association of improved prognosis with plasmacytic infiltrates has been classically linked with the rare medullary carcinoma subtype but is also evident in the smaller infiltrated fraction of the more abundant nonmedullary (not otherwise specified) tumors. It is our hypothesis that these plasma cell (PC) infiltrates represent a host humoral response driven by one or more tumor-derived neoantigens. As the index study group, two primary medullary carcinoma tumors were examined. Immunophenotyping confirmed a large number of IgG PCs in contradistinction to normal breast, which typically contains a lesser number of mainly IgA isotypes. IgG heavy and light chains were expressed as combinatorial phage Fab libraries. VH and VL sequences showed a preponderance of clonal groups in both patients, as identified by germ-line gene usage and junctional mutation patterns. Panning of phage Fab libraries against purified antigens excluded Her2/neu and p53 as the eliciting antigen, and failure of clonal enrichment by cell panning suggested that the neoantigen was not membrane expressed or was expressed at low levels. Cognate, original VH+VL pairs were obtained by single cell PCR of tumor PCs, which showed overlap with the pooled IgG libraries. Tumor-derived IgG V genes exhibited mutational patterns that were consistent with antigenic selection and affinity maturation. Where examined, IgG1 was the predominant isotype, consistent with a T-dependent (i.e., protein) antigen. From these data, we infer that the breast tumor PC infiltrates of the medullary carcinoma subtype are compatible with an autogenic tumor neoantigen-driven humoral immune response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11691809

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

Review 1.  Leukocytes in mammary development and cancer.

Authors:  Lisa M Coussens; Jeffrey W Pollard
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-03-01       Impact factor: 10.005

Review 2.  B lymphocytes and cancer: a love-hate relationship.

Authors:  Grace J Yuen; Ezana Demissie; Shiv Pillai
Journal:  Trends Cancer       Date:  2016-12

3.  Lipid Metabolism in Tumor-Associated B Cells.

Authors:  Fan Yang; Fang Wan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  The immune contexture in human tumours: impact on clinical outcome.

Authors:  Wolf Herman Fridman; Franck Pagès; Catherine Sautès-Fridman; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2012-03-15       Impact factor: 60.716

5.  In situ isolation of immunoglobulin sequences expressed by single tumor-infiltrating B cells using laser-assisted microdissection.

Authors:  Philippa M O'Brien; David W M Millan; Jonathon A Davis; M Saveria Campo
Journal:  Mol Biotechnol       Date:  2005-02       Impact factor: 2.695

6.  Tumor-infiltrating B cells come into vogue.

Authors:  Michael Linnebacher
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 7.  Neurotransmitters as regulators of tumor angiogenesis and immunity: the role of catecholamines.

Authors:  Chandrani Sarkar; Debanjan Chakroborty; Sujit Basu
Journal:  J Neuroimmune Pharmacol       Date:  2012-08-11       Impact factor: 4.147

8.  Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast.

Authors:  Kok Haw Jonathan Lim; Premasiri Upali Telisinghe; Muhd Syafiq Abdullah; Ranjan Ramasamy
Journal:  Cancer Immun       Date:  2010-01-22

9.  Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer.

Authors:  Michael D Iglesia; Benjamin G Vincent; Joel S Parker; Katherine A Hoadley; Lisa A Carey; Charles M Perou; Jonathan S Serody
Journal:  Clin Cancer Res       Date:  2014-06-10       Impact factor: 12.531

10.  A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer.

Authors:  S Hernández-Prieto; A Romera; M Ferrer; J L Subiza; J A López-Asenjo; J R Jarabo; A M Gómez; Elena M Molina; J Puente; J L González-Larriba; F Hernando; B Pérez-Villamil; E Díaz-Rubio; J Sanz-Ortega
Journal:  Clin Transl Oncol       Date:  2014-10-10       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.